Test Report – Insights Into Breast Cancer
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Southwest March 1, 2021
Meeting Chair
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA
Test Chair 2
Test Name 2
Test Location 2
Central April 7, 2021
Meeting Chair
Debu Tripathy, MD
MD Anderson Cancer Center, Houston, TX
Region 3 test test date
Faculty Members
Faculty member content goes here.
More Info
- Virtual Series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Info
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
Report Snapshot
- A virtual, moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained:
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region
